Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1382-1397
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1382
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1382
Figure 5 Pathologic gene patterns shared in the non-alcoholic fatty liver disease and non-alcoholic steatohepatitis meta-analyeses are highlighted above.
This dataset was inputted in clue.io to identify potential drug targets. We found riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as drugs that best targeted the gene expression above.
- Citation: Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E. Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 2022; 14(7): 1382-1397
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1382.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1382